Provided by Tiger Trade Technology Pte. Ltd.

Pfizer

27.72
+0.07000.25%
Post-market: 27.72-0.0031-0.01%16:44 EDT
Volume:25.13M
Turnover:693.75M
Market Cap:157.61B
PE:36.48
High:27.85
Open:27.80
Low:27.42
Close:27.65
52wk High:29.21
52wk Low:23.58
Shares:5.69B
Float Shares:5.64B
Volume Ratio:0.90
T/O Rate:0.45%
Dividend:1.72
Dividend Rate:6.21%
EPS(TTM):0.7599
EPS(LYR):1.36
ROE:5.01%
ROA:5.78%
PB:1.85
PE(LYR):20.32

Loading ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY) and Pfizer (PFE)

TIPRANKS
·
Jun 23

J.P. Morgan Remains a Hold on Pfizer (PFE)

TIPRANKS
·
Jun 23

Pfizer (PFE) Gets a Buy from Jefferies

TIPRANKS
·
Jun 23

Pfizer's Phase 3 Study of Sigvotatug Vedotin Misses Overall Survival Endpoint

MT Newswires Live
·
Jun 23

Pfizer's Lung Cancer Drug Trial Misses Endpoint

Dow Jones
·
Jun 23

Pfizer Inc Shares Fall 1% After the Bell Following Results After Phase 3 Study for Sigvotatug Vedotin Shows Does Not Improve Overall Survival

THOMSON REUTERS
·
Jun 23

Pfizer's experimental drug misses main goal of lung cancer trial

Reuters
·
Jun 23

Pfizer says sigvotatug vedotin did not show big improvement in primary endpoint

TIPRANKS
·
Jun 23

Pfizer says Phase 3 SigVie-002 trial misses overall survival endpoint for sigvotatug vedotin in metastatic NSCLC

Reuters
·
Jun 23

Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

THOMSON REUTERS
·
Jun 23

Pfizer - Sigvotatug Vedotin Shows Manageable Safety Profile Consistent With Prior Studies

THOMSON REUTERS
·
Jun 23

Pfizer - Sigvotatug Vedotin Does Not Improve Overall Survival Versus Docetaxel in Phase 3 Study

THOMSON REUTERS
·
Jun 23

Pfizer - Stronger Trend for Os and Pfs With Sigvotatug Vedotin in Second-Line Nsclc Patients

THOMSON REUTERS
·
Jun 23

Pfizer - No Clear Ib6 Expression-Response Relationship Observed in Exploratory Analysis

THOMSON REUTERS
·
Jun 23

Asad Haider Reiterates Hold on PFE, Keeps 12-Month Price Target Unchanged at $26 Amid CFO Transition and Clinical Upside Uncertainty

TIPRANKS
·
Jun 21

Pfizer’s AI Upgrades and Pipeline Bets Stir Investor Hopes

TIPRANKS
·
Jun 20

Pfizer (PFE) Stock Could Be 10% Undervalued After CFO Exit Raises Execution Questions

Simply Wall St.
·
Jun 20

BRIEF-CMA Says Court Of Appeal Ruled Tribunal Was "Wrong To Set Aside [CMA's] Decision" In Relation To Investigation Into Phenytoin

Reuters
·
Jun 19

Regulator wins decade-long pricing tussle with Pfizer

cityam
·
Jun 19

NYSE Most Active Issues

Dow Jones
·
Jun 19